Bank of America Securities is urging investors to look beyond crowded artificial intelligence trades, arguing that value stocks, biotech, regional banks, select credit and commodities offer attractive ...

The drugmaker should significantly mitigate its most important risk as it develops new products.

Amgen, Gilead and Vertex all show up in the same note, but the bank isn't treating them equally.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t ...

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside. Read more on ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Scientists at the Department of Energy's Oak Ridge National Laboratory have created a platform that pinpoints genetic ...

This is not possible without a steadfast commitment from our partners in the federal government and private industry. It’s important to acknowledge and evaluate the current constraints. On the ...

Georgia Witchel's Mantis Biotech makes Parva, consumer software that reads how a person types and clicks to flag cognitive change relative to their own baseline, not a population average, largely ...